Advertisement

Abnormality in Immunoregulatory Cells in Human Malignancies

  • Sudhir Gupta
Part of the Advances in Immunity and Cancer Therapy book series (IMMUNITY, volume 2)

Abstract

Immune regulation may be defined as a process that determines the magnitude, intensity, duration, and tempo of immune responses after the system has been disturbed by an antigen. There are several mechanisms that are involved in immune regulation; their discussion is out of the scope of this chapter, and interested readers are referred to a concise review (1). These immunoregulatory T cell subsets either enhance or suppress the B cell differentiation to plasma cells and T cell proliferation to mitogens, antigens, and alloantigens (2). In normal immune hemostasis, there is a delicate balance between helper and suppressor functions. Immunoregulatory T cell subsets are identified by the presence of receptors for immunoglobulin isotypes (3–5), and the differentiation antigens are defined with monoclonal antibodies (6). A list of these markers is shown in Table 2.1. More recently it has become apparent that even the so-called helper/inducer T cells (OKT4+, T4+, Leu 3+) and suppressor/cytotoxic (OKT8+, T8+, Leu 2+, OKTS+) T cells are not functionally homogeneous. The subject of functional heterogeneity of T4+ and T8+ T cells have recently been reviewed (7). In this chapter, I will discuss primarily the disorders of immunoregulatory T cell subsets and of macrophages in various malignancies, including those stems from normal immunoregulatory T cell subsets themselves.

Keywords

Chronic Lymphocytic Leukemia Suppressor Cell Mycosis Fungoides Cell Chronic Lymphocytic Leukemia Purify Protein Derivative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gupta S, Good RA: What is immune regulation? Triangle 20: 55–58, 1981.PubMedGoogle Scholar
  2. 2.
    Broder S, Waldmann TA: The suppressor cell network in cancer. N Engl J Med 299: 1281–1335, 1978.PubMedCrossRefGoogle Scholar
  3. 3.
    Gupta S: Functionally distinct subpopulation of human T lymphocytes. A review. Clin Bull 8: 100–107, 1978.PubMedGoogle Scholar
  4. 4.
    Gupta S, Good RA: Human T cell subpopulations as defined by Fc receptors. Thymus 1: 135–149, 1979.PubMedGoogle Scholar
  5. 5.
    Moretta L, Ferrarini M, Cooper MD: Characterization of human T cell subpopulations as defined by specific receptors for immunoglobulin. Contemp Topics Immunobiol 8: 19–53, 1978.Google Scholar
  6. 6.
    Reinherz EL, Schlossman SF: The differentiation and function of human T lymphocytes. Cell 19: 821–827, 1980.PubMedCrossRefGoogle Scholar
  7. 7.
    Gupta S: Lymphocyte subpopulations: Phenotypic expression and functions in health and rheumatic disease. In Gupta S, Talal N (eds): Immunology of Rheumatic Diseases, pp 21–83. New York: Plenum Press, 1985.CrossRefGoogle Scholar
  8. 8.
    Broder S, Poplack D, Whang-Peng J, Durm H, Goldman C, Muul L, Waldmann TA: Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. N Engl J Med 298: 66–72, 1978.PubMedCrossRefGoogle Scholar
  9. 9.
    Uchiyama T, Sagawa K, Takatsuki K: Effect of adult T cell leukemia cells on pokeweed mitogen-induced normal B cell differentiation. Clin Immunol Immunopathol 10: 24–34, 1978.PubMedCrossRefGoogle Scholar
  10. 10.
    Reinhertz EL, Nadler LM, Sallan SE, Schlossman SF: Subset derivation of T cell acute lymphoblastic leukemia in man. J Clin Invest 64: 392–397, 1979.CrossRefGoogle Scholar
  11. 11.
    Beck JD, Haghbin M, Wollner N, Mertelsmann R, Garrett T, Koziner B, Clarkson B, Miller D, Good RA, Gupta S: Subpopulations of human T lymphocytes. VI. Analysis of cell markers in acute lymphoblastic leukemia with special reference to Fc receptor expression on E-rosette forming blasts. Cancer 46: 45–49, 1980.PubMedCrossRefGoogle Scholar
  12. 12.
    Moretta L, Mingari MC, Moretta A, Lydyard PM: Receptors for IgM are expressed on acute lymphoblastic leukemic cells having T cell characteristics. Clin Immunol Immunopathol 7: 405–409, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Kaur P, Schulof R, Miller D, Steinhertz P, Good R, Gupta S: Immunoregulatory activity of leukemic blasts from “null” cell acute lymphoblastic leukemia. Cancer 49: 43–47, 1981.CrossRefGoogle Scholar
  14. 14.
    Boumsell L, Bernard A: Surface antigen on human malignant T cells. In Knapp W (ed): Leukemia Markers, pp 129–142. New York: Academic Press, 1981.Google Scholar
  15. 15.
    Herrmann F, Sieber G, Komischke B, Oestsreich R, Ruhl H: T-ALL related to intermediate cortical-medullary thymocytes displaying functional and surface characteristics of suppressor T cells. Acta Haematol 71: 1–7, 1984.PubMedCrossRefGoogle Scholar
  16. 16.
    Buechner SA, Winkelmann RK, Banks PM: T cells in cutaneous lesions of Sézary syndrome and T cell leukemia characterized by monoclonal antibodies. Arch Dermatol 119: 895–900, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T cell leukemia: Clinical and hematological features of 16 cases. Blood 50: 481–492, 1977.PubMedGoogle Scholar
  18. 18.
    Waldmann TA, Greene WC, Sarin PS, Saxinger C, Blayer DW, Blattner WA, Goldman CK, Bongiovanni K, Sharrow S, Depper JM, Leonard W, Uchiama T, Gallo RC: Functional and phenotypic comparison of human T cell leukemia-lymphoma, virus negative Sézary leukemia, and their distinction using anti-Tac monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest 73: 1711–1718, 1984.PubMedCrossRefGoogle Scholar
  19. 19.
    Blayney DW, Jaffe ES, Blattner WA, Cossman J, Robert-Guroff M, Longo DL, Bunn PA Jr, Gallo RC: The human T cell leukemia/lymphoma virus associated with American adult T cell leukemia/lymphoma. Blood 62: 401–405, 1983.PubMedGoogle Scholar
  20. 20.
    Mizushima K, Takaya Y, Asano T, Sinohara Y, Motoi S, Suzuki S, Ota Z, Yano K: Detection of DR antigen on leukemic cells from a patient suffering from adult T cell leukemia and progressive systemic sclerosis. Acta Med Okayama 37: 401–407, 1983.PubMedGoogle Scholar
  21. 21.
    Miedema F, Terpstra FG, Suit JW, Daenen S, Gerrits W, Hegde U, Matutes E, Catovsky D, Greaves MF, Melief CJ: Functional properties of neoplastic T cells in adult T cell lymphoma/leukemia patients from Caribbean. Blood 63: 477–481, 1984.PubMedGoogle Scholar
  22. 22.
    Swerdlow SH, Haeshaw JA, Rohatinar AZ, Lister TA, Stansfield AG: Caribbean T cell lymphoma/leukemia. Cancer 54: 687–696, 1984.PubMedCrossRefGoogle Scholar
  23. 23.
    Broder S, Edelson R, Lutzner MA, Nelson DL, MacDermott RP, Durm ME, Goldman CK, Meade BD, Waldmann TA: The Sézary syndrome. A malignant proliferation of helper T cells. J Clin Invest 58: 1297–1306, 1976.PubMedCrossRefGoogle Scholar
  24. 24.
    Lawrence EC, Broder S, Jaffe ES, Braylan RC, Dobbins WO, Young RC, Waldmann TA: Evolution of a lymphoma with helper T cell characteristics in Sézary syndrome. Blood 52: 481–492, 1978.PubMedGoogle Scholar
  25. 25.
    Mitsuya H, Sato M, Hirano T, Fujimoto K, Kawano F, Kishimoto S: Evidence for a malignant proliferation of IgE class specific helper T cells in a patient with Sézary syndrome exhibiting massive hyperimmunoglobulinemia E. Clin Immunol Immunopathol 26: 171–183, 1983.CrossRefGoogle Scholar
  26. 26.
    Gupta S, Safai B, Good RA: Subpopulations of human T lymphocytes. IV. Quantitation and distribution in mycosis fungoides and Sézary syndrome. Cell Immunol 39: 18–26, 1978.PubMedCrossRefGoogle Scholar
  27. 27.
    Kermani-Arab V, Robert JL, Hanifin JM, Leslie GA: Lack of functional immunoregulatory cells in a patient with mycosis fungoides and circulating Sézary cells. Brief communication. J Natl Cancer Inst 60: 1295–1299, 1978.PubMedGoogle Scholar
  28. 28.
    Farnarier-Seidel C, Kaplanski S, Goldstein MM, Jancovici E, Sayag J, Depieds R: An OKT4+ T cell population with suppressor activity in Sézary syndrome. Scand J Immunol 18: 389–398, 1983.PubMedCrossRefGoogle Scholar
  29. 29.
    Hoffman FM, Meyer PR, Yanagihara E, Modlin RL, Rea T-H, Parker JW, Leuker RJ, Taylor RC: Demonstration of a subpopulation of Ia+ T helper cells in mycosis fungoides and Sézary syndrome. Am J Dermatopathol 5: 135–143, 1983.CrossRefGoogle Scholar
  30. 30.
    Yanagihara ET, Parker JW, Yeyer PR, Cain MJ, Hofman F, Lukes RJ: Mycosis fungoides/Sézary syndrome progressing to immunoblastic sarcoma. A T cell lymphoproliferation with both helper and suppressor phenotypes. Am J Clin Pathol 81: 249–257, 1984.PubMedGoogle Scholar
  31. 31.
    Fiorini G, Riva F, Paracchini ML, Marinig C: Monoclonal antibody-defined peripheral blood T lymphocyte subpopulations in patients with mycosis fungoides. Oncology 40: 400–403, 1983.PubMedCrossRefGoogle Scholar
  32. 32.
    Bennett SR, Greer JP, Stein RS, Glick AD, Consar JB, Collins RD: Death due to splenic rupture in suppressor cell mycosis fungoides: A case report. Am J Clin Pathol 82: 104–109, 1984.PubMedGoogle Scholar
  33. 33.
    Gupta S: Immunodeficiencies in Hodgkin’s disease. I. T cell-mediated immunity. Clin Bull 11: 57–65, 1981.Google Scholar
  34. 34.
    Twomey JJ, Laughter AH, Farrow S, Douglas CC: Hodgkin’s disease: An immunodepleting and immunosuppressive disorder. J Clin Invest 56: 467–475, 1975.PubMedCrossRefGoogle Scholar
  35. 35.
    Hillinger SM, Herzig GP: Impaired cell-mediated immunity in Hodgkin’s disease mediated by suppressor lymphocytes and monocytes. J Clin Invest 61: 1620–1627, 1978.PubMedCrossRefGoogle Scholar
  36. 36.
    Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC: Prostaglandin-producing suppressor cells in Hodgkin’s disease. N Engl J Med 397: 963–968, 1977.CrossRefGoogle Scholar
  37. 37.
    Haim N, Meidan A, Samuelly B, Segal R, Mekori T, Robinson E: Prostaglandin related and adherent cell suppressor system in apparently cured Hodgkin’s disease patients. J Biol Resp Med 3: 219–225, 1984.Google Scholar
  38. 38.
    Gupta S: Subpopulations of human T lymphocytes. XVI. Maldistribution of T cell subsets associated with abnormal locomotion of T cells in untreated adult patients with Hodgkin’s disease. Clin Exp Immunol 42: 186–194, 1980.PubMedGoogle Scholar
  39. 39.
    Gupta S, Tan C: Subpopulations of human T lymphocytes. XIV. Abnormality of Tcell locomotion and of distribution of subpopulations of T and B lymphocytes in peripheral blood and spleen from children with untreated Hodgkin’s disease. Immunol Immunopathol 15: 133–143, 1980.CrossRefGoogle Scholar
  40. 40.
    Lauria F, Fao R, Gobbi M, Camaschella C, Lusso P, Raspadori D, Tura S: Increased proportion of suppressor/cytotoxic (OKT8+) cells in patients with Hodgkin’s disease in long lasting remission. Cancer 52: 1385–1388, 1983.PubMedCrossRefGoogle Scholar
  41. 41.
    Posner MR, Reinherz E, Lane H, Manch P, Hellman S, Schlossman SF: Circulating lymphocyte populations in Hodgkin’s disease, after mantle and paraaortic irradiation. Blood 61: 705–708, 1983.PubMedGoogle Scholar
  42. 42.
    Herrmann F, Sieber G, Janer B, Lochner A, Komischke B, Ruhl H: Evaluation of the circulating and splenic lymphocyte subpopulations in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease using monoclonal antibodies. Blut 47: 41–51, 1983.PubMedCrossRefGoogle Scholar
  43. 43.
    Romagnani S, Del-Prete GF, Maggi E, Bosi A, Bernardi F, Ponticelli P, Di-Loolo S, Ricci M: Displacement of T lymphocytes with helper/inducer phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin’s disease. Scand J Haematol 31: 305–314, 1983.PubMedCrossRefGoogle Scholar
  44. 44.
    Schulof RS, Lee BJ, Lacher MJ, Straus DJ, Clarkson BD, Good RA, Gupta S: Concanavalin A induced suppressor activity in Hodgkin’s disease. Clin Immunol Immunopathol 16: 454–462, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Akbar AN, Jones DB, Wright DH: Spontaneous and concanavalin A-induced suppressor activity in control and Hodgkin’s disease patients. BrJ Cancer 49: 349–356, 1984.CrossRefGoogle Scholar
  46. 46.
    Schulof RS, Bockman RS, Garofalo JA, Cirrincione C, Cummingham-Rundles S, Rernandes G, Day NK, Pinsky CM, Incefy GS, Thaler HT, Clarkson BD, Lee BJ, Good RA, Gupta S: Multivariate analysis of T cell fun factors in Hodgkin’s disease. Cancer 48: 964–973, 1981.PubMedCrossRefGoogle Scholar
  47. 47.
    Whisler RL, Murray JL, Roach RW, Balcerzak SP: Characterization of multiple immune defects in human malignant lymphoma. Cancer 53: 2628–2634, 1984.PubMedCrossRefGoogle Scholar
  48. 48.
    Gupta S, Good RA: Immunodeficiencies associaterd with chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. In Twomey JJ, Good RA (eds): Immunopathology of Lymphoreticular Neoplasm. Comprehensive Immunology, vol 4, pp 563–586. New York: Plenum Press, 1978.Google Scholar
  49. 49.
    Chiorazzi N, Fu SM, Montazeri G, Kunkel HG, Rai K, Gee T: T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol 122: 1087–1089, 1979.PubMedGoogle Scholar
  50. 50.
    Gorski A, Somkowski M, Leszko B, Korczak-Kowalska G, Nowaczyk M: Immunoregulatory factors controlling terminal differentiation of malignant B lymphocytes. Immunol Lett 6: 311–315, 1983.PubMedCrossRefGoogle Scholar
  51. 51.
    Lauria F, Fao R, Mantovani V, Fierro MT, Catovsky D, Tura S: T cell functional abnormality in B chronic lymphocytic leukemia: Evidence of a defect of the T helper subset. Br J Haematol 54: 277–283, 1983.PubMedCrossRefGoogle Scholar
  52. 52.
    Sieber G, Herrmann F: Increased suppressor and normal helper T cell activity in patients with B cell chronic lymphatic leukemia. (B-CLL). Br J Haematol 55: 561–563, 1983.PubMedCrossRefGoogle Scholar
  53. 53.
    Semenzato G, Pezzutoo A, Fao R, Lauria F, Raimondi R: T lymphocytes in B-cell chronic lymphocytic leukemia: Characterization by monoclonal antibodies and correlation with Fc receptors. Clin Immunol Immunopathol 26: 155–161, 1983.PubMedCrossRefGoogle Scholar
  54. 54.
    Buchi G, Termine G, Zappala C, Girotto M, Grosso E, Antino R: Spontaneous complete remission of CLL. Report of a case studied with monoclonal antibodies. Acta Haematol 70: 198–201, 1983.PubMedCrossRefGoogle Scholar
  55. 55.
    Kay NE, Hohnson J, Douglas SD: Evidence for excessive T suppressor cell function in chronic lymphocytic leukemia. Blood 54 (Suppl): 102A, 1979.Google Scholar
  56. 56.
    Platsoucas CD, Kempin S, Karanas A, Clarkson BD, Good RA, Gupta S: Receptors for immunoglobulin isotypes on T and B lymphocytes from untreated patients with chronic lymphatic leukemia. Clin Fxp Immunol 40: 256–263, 1980.Google Scholar
  57. 57.
    Fiorilli M, Mistiti JP, Pandolfi F, Semenzalo G, Waldmann TA: In vitro interactions with antigen suppresses the differentiation of chronic lymphocytic leukemia cells secreting monoclonal anti-sheep red blood cell antibody. J Immunol 131: 2046–2049, 1983.PubMedGoogle Scholar
  58. 58.
    Fernandez LA, MacSween JM, Langley GR: Immunoglobulin secretory function of B cells from untreated patients with chronic lymphocytic leukemia and hypogammaglobulinemia: Role of T cells. Blood 62: 767–774, 1983.PubMedGoogle Scholar
  59. 59.
    Faguet GB: Mechanisms of lymphocyte activation. The role of suppressor cells in the proliferative responses of chronic lymphatic leukemia lymphocytes. J Clin Invest 63: 67–74, 1979.PubMedCrossRefGoogle Scholar
  60. 60.
    Scouros MA, Bohleber-Matza M, Murphy SG: Kinetics of protein A activation of mononuclear cells from patients with chronic lymphocytic leukemia. I. CLL B cells are not intrinsically unresponsive to staphylococcal protein A. Leuk Res 7: 703–712, 1983.PubMedCrossRefGoogle Scholar
  61. 61.
    Pandolfi F, Mandelli F, Semenzato G, Ranucci A, Anti F: Classification of patients with T-cell chronic lymphocytic leukemia and expansions of granular lymphocytes: Heterogeneity of Italian cases by a multiparameter analysis. J Clin Immunol 4: 174–184, 1984.PubMedCrossRefGoogle Scholar
  62. 62.
    Vyth-Dreese FA, deVries JE: Phenotypic and functional characterization of HTLV positive neoplastic T cells cultured with interleukin 2. II. Inhibition of lymphoproliferative response. Leuk Res 8: 15–26, 1984.PubMedCrossRefGoogle Scholar
  63. 63.
    Phyliky RL, Li CY, Yam LT: T cell chronic lymphocytic leukemia with morphologic and immunologic characteristics of cytotoxic/suppressor phenotype. Mayo Clin Proc 58: 709–720, 1983.PubMedGoogle Scholar
  64. 64.
    Feller AC, Parwaresch MR, Lennert K: Subtyping of chronic lymphocytic leukemia of T type by dipeptidylamino peptidase IV (DAP IV), monoclonal antibodies, and Fc receptors. Cancer 52: 1609–1612, 1983.PubMedCrossRefGoogle Scholar
  65. 65.
    Wirthmuller R, Denning D, Oertal J, Gerhart H: Dipeptidylaminopeptidase IV (DAP IV) activity in normal and malignant T cell subsets as defined by monoclonal antibodies. Scand J Haematol 31: 197–205, 1983.PubMedCrossRefGoogle Scholar
  66. 66.
    Palutke M, Eisenberg L, Kaplan J, Hussain M, Kithier K, Tabaczka P, Mirachandani I, Tannenbaum D: Natural killer and suppressor T cell chronic lymphocytic leukemia. Blood 62: 627–634, 1983.PubMedGoogle Scholar
  67. 67.
    Gupta S, Fernandes G: Natural killer and antibody-dependent cytotoxic activities in T cell chronic lymphocytic leukemia. J Clin Lab Immunol 12: 155–157, 1983.PubMedGoogle Scholar
  68. 68.
    Bakri K, Ezdinli EZ, Wasser LP, Han T, Sinclair T, Singh S, Ozer H, Minowada J: T suppressor cell chronic lymphocytic leukemia. Phenotypic characterization by monoclonal antibodies. Cancer 54: 282–292, 1984.CrossRefGoogle Scholar
  69. 69.
    Stavem P, Frre O, Brandtzaeg P, Myberg H: T lymphocytes with both helper and suppressor markers on the same cell in chronic lymphocytic leukemia. Scand J Haematol 30: 177–182, 1983.PubMedCrossRefGoogle Scholar
  70. 70.
    Brisbane JU, Berman LD, Osband ME, Neiman RA: T8 chronic lymphocytic leukemia. A distinctive disorder related to T8 lymphocytosis. Am J Clin Pathol 80: 391–396, 1983.PubMedGoogle Scholar
  71. 71.
    Hoffman R, Kopel S, Hsu SD, Daimak N, Zanjani ED: T cell chronic lymphocytic leukemia. Presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood 52: 255–260, 1978.PubMedGoogle Scholar
  72. 72.
    Galton DA, Goldman JM, Wiltshaw E, Catovsky D, Henry K, Goldenberg GJ: Prolymphocytic leukemia. Br J Haematol 27: 7–24, 1974.PubMedCrossRefGoogle Scholar
  73. 73.
    Tsai LM, Tsai CC, Hyde TP, Thomas LA, Broun GO: T cell prolymphocytic leukemia with helper cell phenotype and a review of the literature. Cancer 54: 463–470, 1984.PubMedCrossRefGoogle Scholar
  74. 74.
    Volk JR, Kjeldsberg CR, Eyre HJ, Marty J: T cell prolymphocytic leukemia. Clinical and immunologic characterization. Cancer 52: 2049–2054, 1983.PubMedCrossRefGoogle Scholar
  75. 75.
    Zamkoff KW, Poiesz BJ, Ruscetti FW, Moore JL, Davey FR, Planas AT, Lamber-son H: Functional diversity within the suppressor phenotype as defined by monoclonal antibody in T cell prolymphocytic leukemia. Am J Hematol 16: 409–417, 1984.PubMedCrossRefGoogle Scholar
  76. 76.
    Planas AT, Zamkoff KW, Poiesz BJ, Kurec AS, Darcy FR: T cell prolymphocytic leukemia with a suppressor phenotype. Ann Clin Lab Sci 13: 193–200, 1983.PubMedGoogle Scholar
  77. 77.
    Corwin DJ, Kadin ME, Andres TL: T cell prolymphocytic leukemia: 2 cases having a postthymic helper phenotype with complement receptors and 14Q+ chromosome abnormality. Acta Haematol 70: 43–49, 1983.PubMedCrossRefGoogle Scholar
  78. 78.
    Bhoopalam N, Yakulis V, Costea N, Heller P: Surface immunoglobulins of circulating lymphocytes in mouse plasmacytoma. II. The influence of plasmacytoma RNA on surface immunoglobulins of lymphocytes. Blood 39: 465–471, 1972.PubMedGoogle Scholar
  79. 79.
    Giacomoni D, Yakulis V, Wang SR, Cooke A, Dray S, Heller P: In vitro conversion of normal mouse lymphocytes by plasmacytoma RNA to express idiotypic specificities on their surface characteristics of the plasmacytoma immunoglobulin. Cell Immunol 11: 389–400, 1974.PubMedCrossRefGoogle Scholar
  80. 80.
    Salmon SE: Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Sem Hematol 10: 135–177, 1973.Google Scholar
  81. 81.
    Tanapatchaiyapong P, Zolla S: Humoral immunosuppressive substance in mice bearing plasmacytomas. Science 186: 748–750, 1974.PubMedCrossRefGoogle Scholar
  82. 82.
    Broder S, Humphrye R, Durm M, Blackman M, Meade B, Goldman C, Strober W, Waldman TA: Impaired synthesis of polyclonal (nonparaprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. Role of suppressor cells. N Engl J Med 293: 877–892, 1975.CrossRefGoogle Scholar
  83. 83.
    Krakauer RS, Strober W, Waldmann LA: Hypogammaglobulinemia in experimental myeloma. The role of suppressor factors from mononuclear phagocytes. J Immunol 118: 1385–1390, 1977.PubMedGoogle Scholar
  84. 84.
    Paglieroni T, MacKenzie MR: Studies on the pathogenesis of an immune defect in multiple myeloma. J Clin Invest 59: 1120–1133, 1977.PubMedCrossRefGoogle Scholar
  85. 85.
    Mills KH, Cawley JC: Abnormal monoclonal antibody-defined helper/suppressor T cell subpopulations in multiple myeloma: Relationship to treatment and clinical stage. Br J Haematol 53: 271–275, 1983.PubMedCrossRefGoogle Scholar
  86. 86.
    Lauria F, Fao R, Cavo M, Gobbi M, Raspadori D, Giubellino MC, Tazzari PL, Tura S: Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: Correlation with clinical stages of the disease. Clin Exp Immunol 56: 653–658, 1984.PubMedGoogle Scholar
  87. 87.
    Jerrells TR, Dean JH, Richardson GL, McGoy JL, Herberman RB: Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients. J Natl Cancer Inst 61: 1001–1009, 1978.PubMedGoogle Scholar
  88. 88.
    Blomgren ME, Baral E, Petrim B, Wasserman J: Impaired lymphocyte response to PPD tuberculin in advanced breast carcinoma. Increased reactivity after depletion of phagocytic or adherent cells. Clin Oncol 2: 379, 1974.Google Scholar
  89. 89.
    Gupta S, Cunningham-Rundles S: Subpopulations of human T lymphocytes. XIX. T cells and T cells with receptors for IgMFc (Tµ), IgGFc (T’y), or IgAFc (Ta) in the peripheral blood and regional lymph nodes from patients with untreated breast cancer. J Natl Cancer Inst 69: 1261–1264, 1982.PubMedGoogle Scholar
  90. 90.
    Gupta S, Cunningham-Rundles S: Deficient concanavalin A-induced suppressor cell activity in women with untreated breast cancer. J Lab Clin Immunol 9: 159–161, 1982.Google Scholar
  91. 91.
    Petrini B, Wasserman J, Blomgren H, Glas U: Changes in blood T cell subsets following radiation therapy for breast cancer. Cancer Lett 19: 27–31, 1983.PubMedCrossRefGoogle Scholar
  92. 92.
    Giorno R: Mononuclear cells in malignant and benign tissue. Arch Pathol Lab Med 107: 415–417, 1983.PubMedGoogle Scholar
  93. 93.
    Berlinger NT, Lopez C, Good RA: Facilitation or attenuation of mixed leukocyte culture responsiveness by adherent cells. Nature 260: 145–146, 1976.PubMedCrossRefGoogle Scholar
  94. 94.
    Berlinger NT, Hilal EY, Oettgen HF, Good RA: Deficient cell-mediated immunity in head and neck cancer patients secondary to autologous suppressive immune cells. Larynogoscope 88: 470, 1978.CrossRefGoogle Scholar
  95. 95.
    Quan PC, Burtin P: Demonstration of nonspecific suppressor cells in the peripheral lymphocytes of cancer patients. Cancer Res 38: 288–296, 1978.PubMedGoogle Scholar
  96. 96.
    Pierri I, Cordone G, Rogna S, Pende D, Garaventa G, Barabino A, Indiveri F: Decreased sensitivity of T lymphocytes to normal adherent suppressor cells in patients with head and neck cancer. Cancer Detect Prey 7: 73–78, 1984.Google Scholar
  97. 97.
    Rabin BS, Johnson J, Claassen D: Identification of subsets of lymphocytes infiltrating head and neck tumor tissue: A preliminary report. Larynogoscope 94: 688–690, 1984.Google Scholar
  98. 98.
    Balch CM, Doughtery PA, Cloud GA, Talden AB: Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95: 71–77, 1984.PubMedGoogle Scholar
  99. 99.
    Berlinger NT, Lopez C, Lipkin M, Vogel JE, Good RA: Defective recognition immunity in family aggregates of colon carcinoma. J Clin Invest 59: 761–769, 1977.PubMedCrossRefGoogle Scholar
  100. 100.
    Pero R, Miller D, Lipkin M, Markowitz M, Gupta S, Enkar W, Good RA: A reduced capacity for DNA repair synthesis in patients with or genetically predisposed to colorectal cancer. J Natl Cancer Inst 5: 857–875, 1983.Google Scholar
  101. 101.
    Einhorn S, Wasserman J, Lundell G, Blomgren H, Cedermark B, Jarstrand C, Petrini B, Strander H, Theve T, Ohman U: Treatment of patients with disseminated colorectal cancer with recombinant alpha-2 interferon. Studies on the immune system. Int J Cancer 33: 251–256, 1984.PubMedCrossRefGoogle Scholar
  102. 102.
    Ostenson RC, Lum LG: In vitro differences in lymphocyte subpopulations reactivity in lung cancer patients: Purified protein derivative-specific suppressor T lymphocytes in patients who received Bacillus Calmette-Guerin. Clin Immunol Immunopathol 30: 233–240, 1984.PubMedCrossRefGoogle Scholar
  103. 103.
    Minnassian AA, Kadagidze ZG: Suppressor cells in melanoma and lung cancer: Correlation with the clinical stage. Neoplasma 30: 153–158, 1983.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1986

Authors and Affiliations

  • Sudhir Gupta

There are no affiliations available

Personalised recommendations